Lipoprotein-apheresis reduces circulating microparticles in individuals with familial hypercholesterolemia

Journal of Lipid Research

Volumn 55, Issue 10, 2014, Pages 2064-2072

  Connolly, Katherine D ^a   Willis, Gareth R ^a   Datta, Dev B N ^b   Ellins, Elizabeth A ^a,c   Ladell, Kristin ^a   Price, David A ^a   Guschina, Irina A ^d   Rees, D Aled ^a   James, Philip E ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b LLANDOUGH HOSPITAL   (United Kingdom)

^c SWANSEA UNIVERSITY   (United Kingdom)

^d CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Exosomes; Extracellular vesicles; Fatty acids; Flow cytometry; Low density lipoprotein apheresis; Microvesicles; Nanoparticle tracking analysis; Phosphatidylserine; Tunable resistive pulse sensing

Indexed keywords

FATTY ACID; FIBRINOGEN RECEPTOR; LIPOCORTIN 5; LOW DENSITY LIPOPROTEIN; NANOPARTICLE; THROMBIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; APHERESIS; ARTICLE; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); FAMILIAL HYPERCHOLESTEROLEMIA; FATTY ACID ANALYSIS; FEMALE; FLOW CYTOMETRY; HUMAN; LIPID COMPOSITION; LIPOPROTEIN APHERESIS; MALE; MEMBRANE MICROPARTICLE; NANOANALYSIS; OUTCOME ASSESSMENT; PARTICLE SIZE; PROTEIN SYNTHESIS INHIBITION; THERAPY EFFECT; AGED; BLOOD; CLINICAL TRIAL; HYPERLIPOPROTEINEMIA TYPE II; METABOLISM; MIDDLE AGED;

AGED; BLOOD COMPONENT REMOVAL; CELL-DERIVED MICROPARTICLES; CHOLESTEROL, LDL; FEMALE; FLOW CYTOMETRY; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; MALE; MIDDLE AGED;

EID: 84907504367     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M049726     Document Type: Article

References (48)

1. Goldstein, J. L., and M. S. Brown. 1979. The LDL receptor locus and the genetics of familial hypercholesterolemia. Annu. Rev. Genet. 13: 259-289.
2. Goldstein, J. L., H. H. Hobbs, and M. S. Brown. 2001. Familial hypercholesterolemia. In The Metabolic and Molecular Bases of Inherited Disease. 8th edition. D. Valle, C. R. Scriver, A. L. Beaudet, et al., editors. McGraw-Hill, New York. 2863-2913.
3. Grundy, S. M., J. I. Cleeman, C. N. Merz, H. B. Brewer, Jr., L. T. Clark, D. B. Hunninghake, R. C. Pasternak, S. C. Smith, Jr., N. J. Stone; National Heart, Lung, and Blood Institute; et al. 2004. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 110: 227-239.
4. Orsoni, A., E. F. Villard, E. Bruckert, P. Robillard, A. Carrie, D. Bonnefont-Rousselot, M. J. Chapman, G. M. Dallinga-Thie, W. Le Goff, and M. Guerin. 2012. Impact of LDL apheresis on atheroprotective reverse cholesterol transport pathway in familial hypercholesterolemia. J. Lipid Res. 53: 767-775.
5. Stoffel, W., H. Borberg, and V. Greve. 1981. Application of specific extracorporeal removal of low density lipoprotein in familial hypercholesterolaemia. Lancet. 2: 1005-1007.
6. Yokoyama, S., R. Hayashi, T. Kikkawa, N. Tani, S. Takada, K. Hatanaka, and A. Yamamoto. 1984. Specific sorbent of apolipoprotein B-containing lipoproteins for plasmapheresis. Characterization and experimental use in hypercholesterolemic rabbits. Arteriosclerosis. 4: 276-282.
7. Eisenhauer, T., V. W. Armstrong, H. Wieland, C. Fuchs, F. Scheler, and D. Seidel. 1987. Selective removal of low density lipoproteins (LDL) by precipitation at low pH: first clinical application of the HELP system. Klin. Wochenschr. 65: 161-168.
8. Agishi, T., I. Kaneko, Y. Hasuo, Y. Hayasaka, T. Sanaka, K. Ota, H. Amemiya, N. Sugino, M. Abe, T. Ono, et al. 2000. Double filtration plasmapheresis. 1980. Ther. Apher. 4: 29-33.
9. Otto, C., P. Kern, R. Bambauer, S. Kallert, P. Schwandt, and K. G. Parhofer. 2003. Efficacy and safety of a new whole-blood low-density lipoprotein apheresis system (Liposorber D) in severe hypercholesterolemia. Artif. Organs. 27: 1116-1122.
10. Kroon, A. A., M. A. van't Hof, P. N. Demacker, and A. F. Stalenhoef. 2000. The rebound of lipoproteins after LDL-apheresis. Kinetics and estimation of mean lipoprotein levels. Atherosclerosis. 152: 519-526.
11. Kroon, A. A., W. R. Aengevaeren, T. van der Werf, G. J. Uijen, J. H. Reiber, A. V. Bruschke, and A. F. Stalenhoef. 1996. LDL-Apheresis Atherosclerosis Regression Study (LAARS). Effect of aggressive versus conventional lipid lowering treatment on coronary atherosclerosis. Circulation. 93: 1826-1835.
12. Thompson, G. R., J. P. Miller, and J. L. Breslow. 1985. Improved survival of patients with homozygous familial hypercholesterolaemia treated with plasma exchange. Br. Med. J. (Clin. Res. Ed.). 291: 1671-1673.
13. Gordon, B. R., S. F. Kelsey, P. C. Dau, A. M. Gotto, Jr., K. Graham, D. R. Illingworth, J. Isaacsohn, P. H. Jones, S. F. Leitman, S. D. Saal, et al. 1998. Long-term effects of low-density lipoprotein apheresis using an automated dextran sulfate cellulose adsorption system. Liposorber Study Group. Am. J. Cardiol. 81: 407-411.
14. Mabuchi, H., J. Koizumi, M. Shimizu, K. Kajinami, S. Miyamoto, K. Ueda, and T. Takegoshi. 1998. Long-term efficacy of low-density lipoprotein apheresis on coronary heart disease in familial hypercholesterolemia. Hokuriku-FH-LDL-Apheresis Study Group. Am. J. Cardiol. 82: 1489-1495.
15. Seidel, D. 1996. H. E. L. P. apheresis therapy in the treatment of severe hypercholesterolemia: 10 years of clinical experience. Artif. Organs. 20: 303-310.
16. van der Pol, E., A. N. Böing, P. Harrison, A. Sturk, and R. Nieuwland. 2012. Classification, functions, and clinical relevance of extracellular vesicles. Pharmacol. Rev. 64: 676-705.
17. Katopodis, J. N., L. Kolodny, W. Jy, L. L. Horstman, E. J. De Marchena, J. G. Tao, D. H. Haynes, and Y. S. Ahn. 1997. Platelet microparticles and calcium homeostasis in acute coronary ischemias. Am. J. Hematol. 54: 95-101.
18. Nomura, S., Y. Komiyama, H. Kagawa, T. Iwasaka, H. Takahashi, and S. Fukuhara. 1997. Microparticles and coronary artery disease. Am. J. Hematol. 56: 296.
19. Sinauridze, E. I., D. A. Kireev, N. Y. Popenko, A. V. Pichugin, M. A. Panteleev, O. V. Krymskaya, and F. I. Ataullakhanov. 2007. Platelet microparticle membranes have 50- to 100-fold higher specific procoagulant activity than activated platelets. Thromb. Haemost. 97: 425-434.
20. Barry, O. P., M. G. Kazanietz, D. Praticò, and G. A. FitzGerald. 1999. Arachidonic acid in platelet microparticles up-regulates cyclooxygenase-2-dependent prostaglandin formation via a protein kinase C/mitogen-activated protein kinase-dependent pathway. J. Biol. Chem. 274: 7545-7556.
21. Suades, R., T. Padró, R. Alonso, J. López-Miranda, P. Mata, and L. Badimon. 2014. Circulating CD45+/CD3+ lymphocyte-derived microparticles map lipid-rich atherosclerotic plaques in FH patients. Thromb. Haemost. 111(1):111-21.
22. Abdelhafeez, A. H., P. M. Jeziorczak, T. R. Schaid, S. L. Hoefs, S. Kaul, R. Nanchal, E. R. Jacobs, and J. C. Densmore. 2014. Clinical CVVH model removes endothelium-derived microparticles from circulation. J. Extracell. Vesicles. 3: 23498.
23. Umekita, K., T. Hidaka, S. Ueno, I. Takajo, Y. Kai, Y. Nagatomo, A. Sawaguchi, T. Suganuma, and A. Okayama. 2009. Leukocytapheresis (LCAP) decreases the level of platelet-derived microparticles (MPs) and increases the level of granulocytes-derived MPs: a possible connection with the effect of LCAP on rheumatoid arthritis. Mod. Rheumatol. 19: 265-272.
24. Lee, W. P., B. N. Datta, B. B. Ong, A. Rees, and J. Halcox. 2011. Defining the role of lipoprotein apheresis in the management of familial hypercholesterolemia. Am. J. Cardiovasc. Drugs. 11: 363-370.
25. Webber, J., and A. Clayton. 2013. How pure are your vesicles? J. Extracell. Vesicles. 2: 19861.
26. Garaiova, I., I. A. Guschina, S. F. Plummer, J. Tang, D. Wang, and N. T. Plummer. 2007. A randomised cross-over trial in healthy adults indicating improved absorption of omega-3 fatty acids by pre-emulsification. Nutr. J. 6: 4.
27. Garbus, J., H. F. Deluca, M. E. Loomans, and F. M. Strong. 1963. The rapid incorporation of phosphate into mitochondrial lipids. J. Biol. Chem. 238: 59-63.
28. Collins, P. W., L. I. Macchiavello, S. J. Lewis, N. J. Macartney, A. G. Saayman, R. Luddington, T. Baglin, and G. P. Findlay. 2006. Global tests of haemostasis in critically ill patients with severe sepsis syndrome compared to controls. Br. J. Haematol. 135: 220-227.
29. Georgescu, A., N. Alexandru, E. Andrei, I. Titorencu, E. Dragan, C. Tarziu, S. Ghiorghe, E. Badila, D. Bartos, and D. Popov. 2012. Circulating microparticles and endothelial progenitor cells in atherosclerosis: pharmacological effects of irbesartan. J. Thromb. Haemost. 10: 680-691.
30. Krauss, R. M., and D. J. Burke. 1982. Identification of multiple subclasses of plasma low density lipoproteins in normal humans. J. Lipid Res. 23: 97-104.
31. Christersson, C., M. Johnell, and A. Siegbahn. 2013. Evaluation of microparticles in whole blood by multicolour flow cytometry assay. Scand. J. Clin. Lab. Invest. 73: 229-239.
32. Robert, S., P. Poncelet, R. Lacroix, L. Arnaud, L. Giraudo, A. Hauchard, J. Sampol, and F. Dignat-George. 2009. Standardization of platelet-derived microparticle counting using calibrated beads and a Cytomics FC500 routine flow cytometer: a first step towards multicenter studies? J. Thromb. Haemost. 7: 190-197.
33. Ichijo, M., S. Ishibashi, T. Ohkubo, S. Nomura, N. Sanjo, T. Yokota, and H. Mizusawa. 2014. Elevated platelet microparticle levels after acute ischemic stroke with concurrent idiopathic thrombocytopenic purpura. J. Stroke Cerebrovasc. Dis. 23: 587-589.
34. Pereira, J., G. Alfaro, M. Goycoolea, T. Quiroga, M. Ocqueteau, L. Massardo, C. Pérez, C. Sáez, O. Panes, V. Matus, et al. 2006. Circulating platelet-derived microparticles in systemic lupus erythematosus. Association with increased thrombin generation and procoagulant state. Thromb. Haemost. 95: 94-99.
35. Namba, M., A. Tanaka, K. Shimada, Y. Ozeki, S. Uehata, T. Sakamoto, Y. Nishida, S. Nomura, and J. Yoshikawa. 2007. Circulating platelet-derived microparticles are associated with atherothrombotic events: a marker for vulnerable blood. Arterioscler. Thromb. Vasc. Biol. 27: 255-256.
36. Nomura, S., M. Suzuki, K. Katsura, G. L. Xie, Y. Miyazaki, T. Miyake, H. Kido, H. Kagawa, and S. Fukuhara. 1995. Platelet-derived microparticles may influence the development of atherosclerosis in diabetes mellitus. Atherosclerosis. 116: 235-240.
37. Sabatier, F., P. Darmon, B. Hugel, V. Combes, M. Sanmarco, J. G. Velut, D. Arnoux, P. Charpiot, J. M. Freyssinet, C. Oliver, et al. 2002. Type 1 and type 2 diabetic patients display different patterns of cellular microparticles. Diabetes. 51: 2840-2845.
38. Tan, K. T., M. H. Tayebjee, H. S. Lim, and G. Y. H. Lip. 2005. Clinically apparent atherosclerotic disease in diabetes is associated with an increase in platelet microparticle levels. Diabet. Med. 22: 1657-1662.
39. Nomura, S., N. N. Tandon, T. Nakamura, J. Cone, S. Fukuhara, and J. Kambayashi. 2001. High-shear-stress-induced activation of platelets and microparticles enhances expression of cell adhesion molecules in THP-1 and endothelial cells. Atherosclerosis. 158: 277-287.
40. Hansen, S. N., and W. S. Harris. 2007. New evidence for the cardiovascular benefits of long chain omega-3 fatty acids. Curr. Atheroscler. Rep. 9: 434-440.
41. De Pascale, C., M. Avella, J. S. Perona, V. Ruiz-Gutierrez, C. P. D. Wheeler-Jones, and K. M. Botham. 2006. Fatty acid composition of chylomicron remnant-like particles influences their uptake and induction of lipid accumulation in macrophages. FEBS J. 273: 5632-5640.
42. Deng, Z-B., X. Zhuang, S. Ju, X. Xiang, J. Mu, Y. Liu, H. Jiang, L. Zhang, J. Mobley, C. McClain, et al. 2013. Exosome-like nanoparticles from intestinal mucosal cells carry prostaglandin E2 and suppress activation of liver NKT cells. J. Immunol. 190: 3579-3589.
43. Nielsen, M. H., H. Beck-Nielsen, M. N. Andersen, and A. Handberg. 2014. A flow cytometric method for characterization of circulating cell-derived microparticles in plasma. J. Extracell. Vesicles. 3: 20795.
44. Novelli, F., T. Neri, L. Tavanti, C. Armani, C. Noce, F. Falaschi, M. L. Bartoli, F. Martino, A. Palla, A. Celi, et al. 2014. Procoagulant, tissue factor-bearing microparticles in bronchoalveolar lavage of interstitial lung disease patients: an observational study. PLoS ONE. 9: e95013.
45. Weiss, R., A. Spittler, G. Schmitz, M. B. Fischer, and V. Weber. 2014. Thrombocyte adhesion and release of extracellular microvesicles correlate with surface morphology of adsorbent polymers for lipid apheresis. Biomacromolecules. 15: 2648-2655.
46. Larson, M. C., J. E. Woodliff, C. A. Hillery, T. J. Kearl, and M. Zhao. 2012. Phosphatidylethanolamine is externalized at the surface of microparticles. Biochim. Biophys. Acta. 1821: 1501-1507.
47. Al Kaabi, A., T. Traupe, M. Stutz, N. Buchs, and M. Heller. 2012. Cause or effect of arteriogenesis: compositional alterations of microparticles from CAD patients undergoing external counterpulsation therapy. PLoS ONE. 7: e46822.
48. Connor, D. E., T. Exner, D. D. F. Ma, and J. E. Joseph. 2010. The majority of circulating platelet-derived microparticles fail to bind annexin V, lack phospholipid-dependent procoagulant activity and demonstrate greater expression of glycoprotein Ib. Thromb. Haemost. 103: 1044-1052.